Mitral stenosis screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
{{Mitral stenosis}} | {{Mitral stenosis}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{S.G.}} | ||
==Overview== | ==Overview== | ||
According to the 2014 and 2017 AHA/ACC [[Medical guideline|Guideline]], screening for mitral stenosis by [[TTE]] is recommended among [[patients]] with [[Medical sign|signs]] or [[Symptom|symptoms]]. " [[Exercise stress testing|Exercise testing]] with [[Doppler]] or [[Invasive (medical)|invasive]] [[Hemodynamic assessment in the cardiac catheterization laboratory|hemodynamic assessment]] is recommended to evaluate the response of the mean [[Mitral valve|mitral]] [[gradient]] and [[pulmonary]] [[artery]] [[pressure]] in [[Patient|patients]] with MS when there is a discrepancy between resting [[Doppler]] [[echocardiographic]] findings and [[clinical]] [[Symptom|symptoms]] or [[Medical sign|signs]]". | According to the 2014 and 2017 AHA/ACC [[Medical guideline|Guideline]], screening for mitral stenosis by [[TTE]] is recommended among [[patients]] with [[Medical sign|signs]] or [[Symptom|symptoms]]. " [[Exercise stress testing|Exercise testing]] with [[Doppler]] or [[Invasive (medical)|invasive]] [[Hemodynamic assessment in the cardiac catheterization laboratory|hemodynamic assessment]] is recommended to evaluate the response of the mean [[Mitral valve|mitral]] [[gradient]] and [[pulmonary]] [[artery]] [[pressure]] in [[Patient|patients]] with MS when there is a discrepancy between resting [[Doppler]] [[echocardiographic]] findings and [[clinical]] [[Symptom|symptoms]] or [[Medical sign|signs]]". | ||
==Screening== | ==Screening== | ||
According to the 2014 and 2017 AHA/ACC [[Medical guideline|Guideline]], screening for mitral stenosis by [[TTE]] is recommended among [[patients]] with [[Medical sign|signs]] or [[Symptom|symptoms]]. " [[Exercise stress testing|Exercise testing]] with [[Doppler]] or [[Invasive (medical)|invasive]] [[Hemodynamic assessment in the cardiac catheterization laboratory|hemodynamic assessment]] is recommended to evaluate the response of the mean [[Mitral valve|mitral]] [[gradient]] and [[pulmonary]] [[artery]] [[pressure]] in [[Patient|patients]] with MS when there is a discrepancy between resting [[Doppler]] [[echocardiographic]] findings and [[clinical]] [[Symptom|symptoms]] or [[Medical sign|signs]]". | According to the 2014 and 2017 AHA/ACC [[Medical guideline|Guideline]], screening for mitral stenosis by [[TTE]] is recommended among [[patients]] with [[Medical sign|signs]] or [[Symptom|symptoms]]. " [[Exercise stress testing|Exercise testing]] with [[Doppler]] or [[Invasive (medical)|invasive]] [[Hemodynamic assessment in the cardiac catheterization laboratory|hemodynamic assessment]] is recommended to evaluate the response of the mean [[Mitral valve|mitral]] [[gradient]] and [[pulmonary]] [[artery]] [[pressure]] in [[Patient|patients]] with MS when there is a discrepancy between resting [[Doppler]] [[echocardiographic]] findings and [[clinical]] [[Symptom|symptoms]] or [[Medical sign|signs]]".<ref name="NishimuraOtto2014">{{cite journal|last1=Nishimura|first1=Rick A.|last2=Otto|first2=Catherine M.|last3=Bonow|first3=Robert O.|last4=Carabello|first4=Blase A.|last5=Erwin|first5=John P.|last6=Guyton|first6=Robert A.|last7=O’Gara|first7=Patrick T.|last8=Ruiz|first8=Carlos E.|last9=Skubas|first9=Nikolaos J.|last10=Sorajja|first10=Paul|last11=Sundt|first11=Thoralf M.|last12=Thomas|first12=James D.|title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary|journal=Circulation|volume=129|issue=23|year=2014|pages=2440–2492|issn=0009-7322|doi=10.1161/CIR.0000000000000029}}</ref><ref name="NishimuraOtto2017">{{cite journal|last1=Nishimura|first1=Rick A.|last2=Otto|first2=Catherine M.|last3=Bonow|first3=Robert O.|last4=Carabello|first4=Blase A.|last5=Erwin|first5=John P.|last6=Fleisher|first6=Lee A.|last7=Jneid|first7=Hani|last8=Mack|first8=Michael J.|last9=McLeod|first9=Christopher J.|last10=O’Gara|first10=Patrick T.|last11=Rigolin|first11=Vera H.|last12=Sundt|first12=Thoralf M.|last13=Thompson|first13=Annemarie|title=2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines|journal=Circulation|volume=135|issue=25|year=2017|issn=0009-7322|doi=10.1161/CIR.0000000000000503}}</ref> | ||
==References== | ==References== | ||
Latest revision as of 20:28, 10 March 2020
|
Mitral Stenosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mitral stenosis screening On the Web |
|
American Roentgen Ray Society Images of Mitral stenosis screening |
|
Risk calculators and risk factors for Mitral stenosis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
According to the 2014 and 2017 AHA/ACC Guideline, screening for mitral stenosis by TTE is recommended among patients with signs or symptoms. " Exercise testing with Doppler or invasive hemodynamic assessment is recommended to evaluate the response of the mean mitral gradient and pulmonary artery pressure in patients with MS when there is a discrepancy between resting Doppler echocardiographic findings and clinical symptoms or signs".
Screening
According to the 2014 and 2017 AHA/ACC Guideline, screening for mitral stenosis by TTE is recommended among patients with signs or symptoms. " Exercise testing with Doppler or invasive hemodynamic assessment is recommended to evaluate the response of the mean mitral gradient and pulmonary artery pressure in patients with MS when there is a discrepancy between resting Doppler echocardiographic findings and clinical symptoms or signs".[1][2]
References
- ↑ Nishimura, Rick A.; Otto, Catherine M.; Bonow, Robert O.; Carabello, Blase A.; Erwin, John P.; Guyton, Robert A.; O’Gara, Patrick T.; Ruiz, Carlos E.; Skubas, Nikolaos J.; Sorajja, Paul; Sundt, Thoralf M.; Thomas, James D. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary". Circulation. 129 (23): 2440–2492. doi:10.1161/CIR.0000000000000029. ISSN 0009-7322.
- ↑ Nishimura, Rick A.; Otto, Catherine M.; Bonow, Robert O.; Carabello, Blase A.; Erwin, John P.; Fleisher, Lee A.; Jneid, Hani; Mack, Michael J.; McLeod, Christopher J.; O’Gara, Patrick T.; Rigolin, Vera H.; Sundt, Thoralf M.; Thompson, Annemarie (2017). "2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Circulation. 135 (25). doi:10.1161/CIR.0000000000000503. ISSN 0009-7322.